Longitudinal measurements of brain atrophy using structural T1-weighted MRI (sMRI) can provide powerful biomarkers for clinical trials in neurodegenerative diseases. Here we use the latest advances in disease progression modelling, specifically the Gaussian Process Progression Model (GPPM), to untangle the effects of inter-subject variability, measurement noise and individual disease stage on longitudinal sMRI measurements in Huntington’s disease (HD). We use GPPM to estimate, for the first time, the relative timescale of sub-cortical atrophy in HD, and identify when sMRI provides additional information to genetics. We conclude that GPPM could increase power over standard imaging biomarkers for clinical trials in HD.
This abstract and the presentation materials are available to members only; a login is required.